Improve the metabolic ability of tumor infiltrated CD8+ cytotoxic T lymphocytes (CTLs) and reduce the expression of PD-1 on CTLs to enhance the anti-tumor immune response in the tumor microenvironments. The gene discussed is CD8A; the disease is neoplasm.